CN101163466B - 2-(2-硝基-4-三氟甲基苯甲酰)-1,3-环己二酮在治疗帕金森病中的用途 - Google Patents

2-(2-硝基-4-三氟甲基苯甲酰)-1,3-环己二酮在治疗帕金森病中的用途 Download PDF

Info

Publication number
CN101163466B
CN101163466B CN2006800133878A CN200680013387A CN101163466B CN 101163466 B CN101163466 B CN 101163466B CN 2006800133878 A CN2006800133878 A CN 2006800133878A CN 200680013387 A CN200680013387 A CN 200680013387A CN 101163466 B CN101163466 B CN 101163466B
Authority
CN
China
Prior art keywords
alkyl
compound
alkoxy
inhibitor
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800133878A
Other languages
English (en)
Chinese (zh)
Other versions
CN101163466A (zh
Inventor
约翰·欧内斯特·多伊
尼克拉斯·克里斯皮尼亚恩·斯特奇斯
金·扎卡里·特拉维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of CN101163466A publication Critical patent/CN101163466A/zh
Application granted granted Critical
Publication of CN101163466B publication Critical patent/CN101163466B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
CN2006800133878A 2005-02-28 2006-02-27 2-(2-硝基-4-三氟甲基苯甲酰)-1,3-环己二酮在治疗帕金森病中的用途 Expired - Fee Related CN101163466B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0504103.3 2005-02-28
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method
PCT/GB2006/000684 WO2006090177A1 (en) 2005-02-28 2006-02-27 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE

Publications (2)

Publication Number Publication Date
CN101163466A CN101163466A (zh) 2008-04-16
CN101163466B true CN101163466B (zh) 2011-12-07

Family

ID=34430351

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800133878A Expired - Fee Related CN101163466B (zh) 2005-02-28 2006-02-27 2-(2-硝基-4-三氟甲基苯甲酰)-1,3-环己二酮在治疗帕金森病中的用途

Country Status (17)

Country Link
US (1) US20090326072A1 (enExample)
EP (1) EP1853241B1 (enExample)
JP (1) JP2008531665A (enExample)
CN (1) CN101163466B (enExample)
AT (1) ATE524171T1 (enExample)
AU (1) AU2006217650B2 (enExample)
BR (1) BRPI0609177A2 (enExample)
CA (1) CA2598517A1 (enExample)
DK (1) DK1853241T3 (enExample)
ES (1) ES2374761T3 (enExample)
GB (1) GB0504103D0 (enExample)
IL (1) IL185410A0 (enExample)
MX (1) MX2007010480A (enExample)
PT (1) PT1853241E (enExample)
RU (1) RU2420272C2 (enExample)
WO (1) WO2006090177A1 (enExample)
ZA (1) ZA200707486B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3311813B1 (en) 2007-08-27 2019-08-07 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
PL2723320T3 (pl) * 2011-06-23 2016-06-30 Swedish Orphan Biovitrum Int Ab Ciekła kompozycja farmaceutyczna zawierająca nityzynon
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
MA42519A (fr) * 2015-07-29 2018-06-06 Takeda Gmbh Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0591275T3 (da) * 1991-06-24 1999-10-11 Zeneca Ltd Anvendelse af 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyklohexandion til behandling af tyrosinæmi samt farmaceutiske sammen
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20050288187A1 (en) * 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
EP1646377A4 (en) * 2003-07-11 2009-09-09 Merck & Co Inc TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE 4 RECEPTOR POSITIVE ALLOSTERIC MODULATOR
AU2006347397A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of HPPD inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Meilan Huang et al.3D-QSAR Studies on 4-hydroxyphenylpyruvate DioxygenaseInhibitors by Comparative Molecular Field Analysis (CoMFA).Bioorganic Medicinal Chemistry Letters 12.2002,(12),2271-2275.
Meilan Huang et al.3D-QSAR Studies on 4-hydroxyphenylpyruvate DioxygenaseInhibitors by Comparative Molecular Field Analysis (CoMFA).Bioorganic Medicinal Chemistry Letters 12.2002,(12),2271-2275. *
李开顺等.帕金森病的药物治疗进展.中国药师2 4.1999,2(4),208-210.
李开顺等.帕金森病的药物治疗进展.中国药师2 4.1999,2(4),208-210. *
陈涛等.多巴胺受体激动剂与帕金森病.国外医学.老年医学分册23 2.2002,23(2),64-68.
陈涛等.多巴胺受体激动剂与帕金森病.国外医学.老年医学分册23 2.2002,23(2),64-68. *
黄美兰等.两类HPPD酶抑制剂的比较分子场分析研究.化学学报60 9.2002,60(9),1558-1563.
黄美兰等.两类HPPD酶抑制剂的比较分子场分析研究.化学学报60 9.2002,60(9),1558-1563. *

Also Published As

Publication number Publication date
BRPI0609177A2 (pt) 2010-02-23
ES2374761T3 (es) 2012-02-21
AU2006217650A1 (en) 2006-08-31
IL185410A0 (en) 2008-08-07
MX2007010480A (es) 2008-02-07
EP1853241B1 (en) 2011-09-14
PT1853241E (pt) 2012-01-11
AU2006217650B2 (en) 2011-06-09
CA2598517A1 (en) 2006-08-31
RU2420272C2 (ru) 2011-06-10
CN101163466A (zh) 2008-04-16
EP1853241A1 (en) 2007-11-14
JP2008531665A (ja) 2008-08-14
ZA200707486B (en) 2009-02-25
WO2006090177A1 (en) 2006-08-31
US20090326072A1 (en) 2009-12-31
DK1853241T3 (da) 2012-01-16
GB0504103D0 (en) 2005-04-06
HK1110211A1 (en) 2008-07-11
RU2007131934A (ru) 2009-02-27
ATE524171T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
JP7761717B2 (ja) 心臓代謝の効率を高めるための組成物および方法
US10005750B2 (en) Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
KR100668539B1 (ko) 과증식성 질환에 대한 조합요법
TWI765995B (zh) 雙環雜芳基衍生物及其製備與用途
TWI286476B (en) Combination of cytochrome P450 dependent protease inhibitors
RU2416606C2 (ru) Соединения и способы для ингибирования взаимодействия bcl белков с компонентами по связыванию
EP2925326A1 (en) Dermatitis treatment
CN101163466B (zh) 2-(2-硝基-4-三氟甲基苯甲酰)-1,3-环己二酮在治疗帕金森病中的用途
WO2023122320A1 (en) Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists
TW202227402A (zh) 嘧啶二酮類衍生物、其製備方法及其在醫藥上的應用
WO2013138600A1 (en) Radioprotector compounds
EP3409671B1 (en) Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
WO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
Dou et al. Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions
EP2233136A1 (en) Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs
JPH10114651A (ja) 哺乳動物細胞の成長を抑制する方法
HK1110211B (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione in the treatment of parkinson's disease
WO2006085510A1 (ja) 過敏性腸症候群の治療薬
HK1142836A (en) Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
FR2827172A1 (fr) Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
JP2011032267A (ja) １１βＨＳＤ１阻害剤およびその用途
TW201014853A (en) Heterocyclic phosphodiesterase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111207

Termination date: 20130227